A user claims to have reversed baldness, possibly due to telogen effluvium recovery after weight loss. Others discuss the potential success of using GHK-Cu for hair regrowth.
The user is experiencing increased hair shedding and is concerned about regression despite consistent use of finasteride, minoxidil, and other treatments. The consensus is that this is likely a temporary shedding phase, and adjustments to the dermarolling frequency are suggested.
The conversation discusses the conflicting information about Zinc's effect on DHT and its role in hair loss. It mentions that Zinc can act as a 5AR inhibitor at high doses but may increase DHT if taken to correct a deficiency, and highlights the importance of nutritional balance for hair health.
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
Diffuse thinners find shopping challenging due to harsh overhead lighting, but H&M's side lighting in fitting rooms is more flattering. Many users humorously suggest banning overhead lighting to improve the shopping experience.
A user discovered they have naturally low DHT levels and is concerned about taking finasteride, which could further lower these levels. They are seeking advice on whether to proceed with the treatment given their hormone levels are within the normal range.
A bodybuilder's hair transplant appears unnatural with a straight hairline and low density, possibly worsened by not using finasteride. The Turkish clinic is criticized for poor design, and the transplant may have been free for promotion.
Topical high-dose vitamin C is discussed as a potential treatment for hair loss due to its ability to inhibit DHT and reduce histamine. Some users express skepticism about its effectiveness compared to treatments like finasteride.
Koshine 826 (Pyrilutamide) is being used by several users to address hair loss, with mixed results on shedding and side effects. Some users report reduced shedding and no side effects, while others experience increased shedding and potential issues with libido and erectile dysfunction.
A 20-year-old male experienced significant hair shedding for nearly 10 months, despite using finasteride, oral minoxidil, and ketoconazole, and is concerned about chronic telogen effluvium. He has been supplementing with vitamins and minerals but remains unsure of the cause.
A 32-year-old female seeks ways to lower DHT without weight gain, experiencing issues with spiro and saw palmetto. Suggestions include topical finasteride, low-dose oral therapies, and checking various health markers.
The user experienced increased hair shedding after switching to a new treatment with higher doses of finasteride (0.3%), minoxidil (7%), ketoconazole (2.2%), and biotin (0.2%). They are curious about the shedding but not concerned about noticeable thinning.
RU58841 is not recommended for use around children due to potential exposure risks. Alternatives like CB-03-01 might be considered, but further research is advised.
A user shared their disappointing results after 1.5 years of hair treatments, including a hair transplant, finasteride, minoxidil, PRP, vegan shampoo, and more. They are considering switching to dutasteride, oral minoxidil, and improving their microneedling routine.
The conversation discusses hair loss treatments, with the original poster considering joining a clinical trial for setipiprant after experiencing side effects from finasteride and disinterest in minoxidil. Some users express skepticism about setipiprant's effectiveness, while others encourage participation in the trial for potential benefits.
A user suggests making a potent sulforaphane topical to degrade DHT and promote hair growth. Another user notes that sulforaphane's low molecular weight might also lower systemic DHT.
A user experienced high estrogen levels after 10 months of taking 1mg oral finasteride but is happy with hair regrowth. They are considering switching to topical finasteride and are also taking DIM and Zinc supplements.
The user has tried various hair loss treatments including topical minoxidil, oral finasteride, oral dutasteride, oral minoxidil, and exosome therapy, but none have been effective. They suspect trichodynia might be preventing these treatments from working.
A 29-year-old is using oral minoxidil, finasteride, hormone replacement therapy (HRT), and microneedling for hair regrowth. They started balding at 20, worsened at 25, and are transitioning with testosterone blockers.
The user stopped using topical finasteride and minoxidil, leading to hair thinning and shedding, and has since restarted the treatment. They are experiencing significant shedding and are seeking advice on whether this is normal and when improvement might occur, while using a regimen that includes Nutrafol, microneedling, Nioxin, and Nizoral.
The conversation discusses the potential of Replicel/Shiseido treatment for hair loss, questioning its effectiveness, whether it grows new follicles, and its market release timeline. It also compares Replicel to other competitors like Kyocera/RIKEN/Tsuji.
A recent discovery in hair cloning identified a previously unknown cell type essential for hair follicle growth, which could potentially make lab-grown hair viable if translated to humans. However, skepticism remains due to past delays and the challenges of replicating results in humans and making the process affordable.
RU58841's side effects may be exaggerated due to anxiety, with some users experiencing no issues and others reporting symptoms like chest pain. RU58841, minoxidil, and finasteride are used for hair loss treatment, with varying individual reactions.
A 15% discount is offered on hair research products like RU58841 and TEMPOL at Chemyo.com. The legality of selling these compounds is confirmed by the seller.
The user experienced hair loss since 2019 and tried finasteride, dutasteride, RU58841, and ketoconazole shampoo without success. A scalp biopsy showed scarring and inflammation from folliculitis, indicating chronic inflammation was affecting treatment effectiveness.
A new stem cell method for culturing hair follicles is being developed as an alternative to Minoxidil, finasteride, and RU58841. There are concerns about its cost and accessibility despite plans for commercialization.
A user with high pre-finasteride estrogen levels is asking if they need to normalize their hormone levels before starting finasteride and whether they should postpone dermarolling until they begin finasteride. The user is 21.5 years old.
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
A 30-year-old man experienced significant hair loss after starting testosterone replacement therapy (TRT), which did not improve with daily finasteride and minoxidil. He is considering restarting TRT and is seeking advice on using pyrilutamide or RU58841 to prevent further hair loss.